# HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/hovon-65-gmmg-hd4-randomized-phase-iii-trial-comparing-bortezomib-doxorubicin/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Pieter Sonneveld,Ingo Schmidt‐Wolf,Bronno van der Holt,Laila el Jarari,Uta Bertsch,Hans Salwender,Sonja Zweegman,Edo Vellenga,Jöerg Schubert,Igor Wolfgang Blau,Asiong Jie,Berna Beverloo,Dirk Hose,Anna Jauch,Helgi van de Velde,M Schaafsma,Walter Lindemann,Marie José Kersten,Ulrich Duehrsen,Michel Delforge,Katja Weisel,Sandra Croockewit,Hans Martin,Shulamit Wittebol,Christof Scheid,Gerard M.J. Bos,Marinus van Marwijk-Kooy,Pierre W. Wijermans,Henk M. Lokhorst,Hartmut Goldschmidt |
| Citations | 88 |
| DOI | 10.1182/blood.v116.21.40.40 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2524357380 |
| Type | article |
| Year | 2010 |

## Paper authors

- [Michel Delforge](https://scholariq.org/researchers/michel-delforge/)

## Paper journal

- [Blood](https://scholariq.org/journals/blood/)

## Paper primary topic

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)

## Paper topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.